Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

<p>BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the […]</p>
<p>The post <a href="https://forextv.com/top-news/biomea-fusion-announces-near-doubling-the-percentage-of-patients-with-durable-hba1c-reduction-in-the-200-mg-dose-cohorts/">Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>